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We have investigated the mechanisms by which subcutaneous immunization of mice with a replication-defective mutant
of herpes simplex virus 1 protects against infection of the eye and latent infection of the trigeminal ganglion following
corneal challenge. First, we have shown that immunization reduces the number of trigeminal ganglion neurons in challenged
animals that express the latency-associated transcript. This indicates that the reduction in the incidence of latent infection
by challenge virus is likely due to immune mechanisms and not saturation of the potential sites of latent infection by the
immunizing mutant virus itself. Second, the duration of protective immunity against acute infection, keratitis, and latent
infection was similar in mice immunized with replication-defective or -competent virus; thus, the replication-defective mutant
virus is able to induce durable immunity apparently without spread in the host. Third, although the mutant virus showed no
evidence of replication in vivo, it was present in footpad tissue in an infectious form for several days. This surprising
observation raises the possibility that continued infection events by input virus over an extended period of time may have
a boosting effect on the developing immune response which could explain, at least in part, the capacity of these replication-
defective mutant viruses to elicit a robust and durable immunity despite their inability to spread within the host. q 1996
Academic Press, Inc.
INTRODUCTION humoral and cellular immune responses, but these have
been shown to decline with time in both animal studies
Herpes simplex virus (HSV) is a common human (Meigner et al., 1987) and human trials (Mertz et al., 1984)
pathogen that causes significant morbidity in its various and have been nonprotective in humans (Mertz et al.,
disease manifestations, which include encephalitis, ker- 1990; Corey, 1991). Recombinant HSV glycoproteins have
atitis, and disseminated disease of the newborn (Roiz- also been employed with potent adjuvants and are pro-
man, 1991; Whitley, 1996). In addition to acute infection tective in animal model systems against acute infection
which initiates at a mucosal or epithelial surface, the and establishment of latent infection (Dix and Mills, 1985;
virus can establish a latent infection of sensory neurons Manservigi et al., 1990a, 1990b; Langenberg et al., 1995;
innervating the infected mucosa. Once latency is estab- Mishkin et al., 1991) and reduce the number of ganglia
lished in the nervous system, the virus is apparently im- expressing the latency-associated transcript (Burke et
pervious to elimination by the host immune response. al., 1991). Both adenoviruses and vaccinia viruses have
Periodic reactivation from latency leads to recurrent epi- been used as vectors to express HSV glycoproteins as
sodes of disease that can be debilitating, as in the case a form of live virus vaccine (Burke, 1992; Gallichan et al.,
of keratitis, the second most common cause of corneal 1993). The vaccinia vectors have been shown to elicit
blindness (Whitley, 1996). Because of the multiple stages immune responses in mice that can reduce disease
of HSV infection, effective vaccination will require the (Cantin et al., 1983; Paoletti et al., 1984; Cremer et al.,
induced immune response to intervene in the establish- 1985; Weir et al., 1989; Blacklaws et al., 1990) and latent
ment of latent infection as well as reduce the severity of infection (Cremer et al., 1985; Blacklaws et al., 1990).
acute disease. Third, the immunity must be long-lasting. In addition, durable immunity was elicited in mice by a
Numerous approaches to immunization against HSV vaccinia virus vector expressing HSV gD (Rooney et al.,
have been tried, including inactivated virus, live attenu- 1988), as would be expected of a live-virus vaccine
ated virus, glycoprotein subunits, and heterologous virus (Burke, 1992). The utility of vaccinia vectors may be lim-
vectors expressing HSV glycoproteins (reviewed in ited by their poor immunogenicity in vaccinia-immune
Burke, 1992). HSV glycoprotein formulations elicit both individuals (Cooney et al., 1993; Hammond et al., 1992).
Replication-impaired mutant HSV strains have also
been examined for their capacity to induce protective
1 Current address: Department of Molecular Microbiology and Immu- immunity against HSV (Nguyen et al., 1992; Morrison and
nology, Saint Louis University School of Medicine, 1402 S. Grand Ave.,
Knipe, 1994; Farrell et al., 1994). These viruses have theSt. Louis, MO 63104.
advantage of expressing virus proteins in an endoge-2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (617) 432-0223. E-mail: dknipe@warren.med.harvard.edu. nously synthesized form to stimulate broader immune
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responses, while possessing the safety of an inactivated strain is a replication-defective mutant of the KOS1.1
strain bearing a deletion in the UL29 gene encoding ICP8vaccine. One form of replication-impaired virus lacks a
viral gene product essential for progeny virus production (Gao and Knipe, 1989). This virus expresses products of
a, b, and g1 gene classes in infected normal cells but(Gao and Knipe, 1989; Rice and Knipe, 1990). These mu-
tants express viral proteins in infected cells but cannot cannot replicate and must be propagated on a cell line,
S2, which is stably transformed with the UL29 gene.replicate in the host, and must be propagated in vitro on
a cell line that complements the defective gene product. Stocks of all viruses were prepared by inoculating Vero
or S2 cell monolayers at low multiplicity of infection (0.1We had previously observed that mice immunized twice
subcutaneously with d301, a replication-defective virus PFU/cell) and incubating at 347 in 199 medium containing
1% FCS. Cells were collected when rounded and de-containing a deletion in the gene encoding ICP8 (Gao
and Knipe, 1989), mount an immune response similar to taching and pelleted at 300 g for 10 min at 47. Cell pellets
were resuspended in culture supernatant plus an equalthat seen in mice immunized with the wt parental strain,
KOS1.1 (Morrison and Knipe, 1994). When challenged 1 volume of sterile nonfat milk (0.91), frozen at 0807,
thawed, and disrupted by sonication (Heat Systems, Far-month later by corneal inoculation of a virulent HSV-1
strain, the mice were completely protected from develop- mingdale, New York) three times for 30 sec each on ice.
Lysates were clarified by centrifugation at 300 g for 10ment of keratitis and encephalitis and from latent infec-
tion of the nervous system (Morrison and Knipe, 1994). min, and aliquots were stored frozen at 0807. Lysate of
uninfected Vero cell monolayers was prepared as a con-A second form of mutant HSV-1 lacking gH, and therefore
capable of undergoing a single round of replication in trol (control cell lysate). Partially purified KOS1.1 was
prepared by harvesting the culture medium of infectedinfected cells, has been shown to protect against disease
in a mouse skin model (Farrell et al., 1994) and a guinea Vero cell monolayers, subjecting the supernatant to low
speed centrifugation to remove detached cells, and thenpig genital model (McLean et al., 1994).
Little is known about the mechanisms by which the pelleting the virus at 27,000 g for 45 min at 47. Virus
pellets were resuspended in 199 medium containing 15%replication-defective mutant viruses induce protective im-
munity against latent infection by challenge virus or, in glycerol, sonicated for 15 sec, and stored at 0807. Wild-
type KOS1.1 and mP strains were titered on Vero cells,general, how live viruses induce protective immunity
against persistent infection. The studies in this report and d301 was titered on S2 cells. Although titered on
Vero cells, KOS1.1 grows equally well on Vero and S2address three questions regarding these mechanisms.
First, does immunization with replication-defective mu- cells (Gao and Knipe, 1991). Because inactivated virus
particles are not effective for induction of immune re-tant HSV reduce establishment of latent infection by the
challenge virus or merely its ability to reactivate? A re- sponses in this system (Morrison and Knipe, 1994), the
number of viral genomes capable of entering cells islated issue is whether the mutant virus establishes la-
tency in the neurons and interferes with establishment a more valid comparison of different viral stocks than
particle:PFU ratios. Cells exposed to equal numbers ofof latent infection by the challenge virus, as hypothesized
for the live attenuated SIV vaccine viruses in T lympho- PFU’s of KOS1.1 wt and d301 contain approximately
equal amounts of viral DNA at 1 hr postinfection (hpi)cytes (Rud et al., 1994). Second, is the immunity induced
by the replication-defective mutant virus durable? Live (Gao and Knipe, 1993). Thus, the two viral stocks seemed
to be comparable in terms of genomes capable of enter-viruses are known to elicit long-lived immunity in the
host while killed or subunit vaccines elicit a less durable ing host cells.
immunity. Replication-defective mutant viruses share
properties with each of these two forms of vaccine in Animals and inoculations
that they infect cells and express endogenous viral anti-
gens like a live virus but fail to spread within the host Female BALB/c mice, 6 weeks of age, were purchased
from the National Cancer Institute (Fredericksburg, MD)similar to an inactivated or subunit vaccine. Thus, it is
not apparent how durable the immune responses to repli- or Taconic (Germantown, NY) and were acclimated 1
week before use. The mice were housed in accordancecation-defective mutant viruses would be. Third, how can
a replication-defective virus induce an immune response with institutional policies and National Institutes of
Health guidelines (Committee on Care and Use of Labo-that is comparable to that induced by a virus that spreads
within the host? ratory Animals, 1985). For immunization, hair on the left
rear flank of each mouse was trimmed and 2 1 106 PFU
of d301 or wt KOS1.1 virus, or an equivalent amount ofMATERIALS AND METHODS
control cell lysate, were inoculated by subcutaneous
Cells and viruses
(s.c.) injection of a 20-ml vol using a 26-gauge needle.
Secondary immunizations were given 4 weeks later inThe wild-type (wt) KOS1.1 (Knipe et al., 1982) and mi-
croplaque (mP) (Hoggan and Roizman, 1959) strains of identical fashion.
At 1, 4, or 7 months after the final immunization, groupsHSV-1 were grown on Vero cell monolayers. The d301
AID VY 7986 / 6a19$$$122 05-16-96 18:44:37 vira AP: Virology
404 MORRISON AND KNIPE
of six to nine mice were anesthetized and challenged by section was collected and hybridized with a 35S-labeled
DNA probe, pIPH (Leib et al., 1989), to detect LAT. Ininoculation onto the scarified corneas of 1 1 105 PFU/
eye of the HSV-1 mP strain as previously described (Coen situ hybridization was performed as previously described
(Haase et al., 1984; Stroop et al., 1984; Leib et al., 1989).et al., 1989), except that the volume of the inoculum was
5 ml.
Statistical analyses
Clinical observations and keratitis scoring
Fisher’s exact test with P values in 1 tail were used toMice were observed daily in the period postchallenge
determine the significance of differences in the propor-for clinical signs of encephalitis: ruffled fur, hunched pos-
tion of latently infected trigeminal ganglia between miceture, ataxia, and anorexia. Keratitis scores, representing
inoculated with control cell lysate and those immunizedboth severity and extent of disease, were determined for
with d301 or KOS1.1. The significance of differences ineach eye of challenged mice as described previously
the number of LAT/ neurons per section was determined(Morrison and Knipe, 1994).
by the two sample t test for independent samples.
Assays of acute and latent infection
Determination of neutralizing antibody titersTo assess acute replication at various times after cor-
neal challenge, the eyes of each mouse were individually
Blood was collected from the tail veins of groups ofswabbed with moistened cotton-tipped applicators. The
five to seven mice at various times after immunization.two swabs from each mouse were placed together in
Sera from each group were pooled and stored at 0207.vials containing 1 ml assay medium (PBS containing 0.1%
When all serum samples had been collected, comple-glucose and 1% FCS) and stored frozen at 0807 until
ment-dependent and -independent neutralizing antibodytime of assay. Viral titers were determined by standard
titers were determined by a CPE inhibition assay. Seraplaque assay on Vero cells (Knipe and Spang, 1982).
were serially diluted in twofold steps beginning at 1:4 inTo assess replication in vivo of mutant and wt virus,
DME supplemented to contain 10% FCS, 20 mM HEPES,groups of mice were injected s.c. in the footpad with 1
100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM1 106 PFU of d301 or KOS1.1 virus. At 5 min after inocula-
glutamine. Aliquots of 25 ml of each dilution were mixedtion, footpad tissue was collected from a pair of animals
with an equal volume of partially purified virus in mediumto assess the amount of recoverable virus. Then at 4 hr
alone or containing complement (1:4 dilution of rabbitand 1, 2, and 3 days after inoculation, pairs of mice were
low-tox H, Cedarlane, Hornby, Ontario, Canada) for finalsacrificed and footpad tissue was collected into vials
concentrations of 21 103 PFU/ml of virus and 1:8 dilutioncontaining 1 ml assay medium and stored at 0807. Viral
of complement. Mixtures containing complement weretiters in the tissues were determined by plaque assay
incubated at 377 for 80 min and mixtures lacking comple-on S2 cells after samples were thawed and disrupted by
ment were incubated at 47 for 80 min. Each was thensonication for 30 sec each.
mixed with an equal vol of a suspension of trypsinizedFor assessment of reactivating virus indicative of latent
Vero cells at 4 1 105/ml, and 100 ml were added toinfection, trigeminal ganglia were removed from animals
individual wells of 96-well flat-bottom tissue culture28 days after corneal challenge and the tissue was enzy-
plates, six replicates per sample, for final concentrationsmatically dissociated by incubation in trypsin and colla-
of 100 PFU/well and 2 1 104 cells/well. After 3 days ofgenase as previously described (Kennedy et al., 1980;
incubation at 377 and 5% CO2 , wells were scored for theLeib et al., 1991), except that after 30-min incubation at
presence of CPE. Titers represent the reciprocal of the377, the tissue was pelleted and half of the dissociation
final serum dilution preventing CPE in 50% of wells asmedium was removed and replaced with serum-free me-
approximated by the method of Reed and Muench (1938).dium, followed by another 30-min incubation. Dissociated
Complement mixed with virus in the absence of HSV-ganglionic cells were added to Vero cell monolayers in
specific serum antibody or in the presence of normal6-well tissue culture dishes (1 ganglion/well). Wells were
mouse serum had no effect on infectivity.observed for the presence of cytopathic effect (CPE) after
11 days of incubation at 377 and 5% CO2 . Wells with no
apparent CPE were collected, sonicated, and cultured on Assays of T cell proliferation
fresh Vero cell monolayers to look for plaque formation.
For assessment of latency-associated transcript (LAT) HSV-specific T cell proliferative responses of spleno-
cytes from two pooled spleens for each immunizationexpression in the trigeminal ganglia indicative of latent
infection, trigeminal ganglia removed from mice immu- group were determined at various times after immuniza-
tion, as described previously (Morrison and Knipe, 1994),nized twice with d301 or control cell lysate and then
challenged 1 month later were frozen and serially sec- except that partially purified virus and control superna-
tant of uninfected cells were used as the in vitro stimuli.tioned at 8 mm using a cryostat microtome. Every other
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TABLE 1
Reduction in Number of LAT/ Neurons in Trigeminal Ganglia of Immunized Micea
Number of Number of LAT/
Immunization sections LAT/ neurons per
group Ganglion examined neurons section Mean { SD
Cell lysate 1 19 520 27.37 19.26 { 11.48
2 14 156 11.14
d301 1 30 11 0.37 0.25 { 0.1
2 30 2 0.07
3 29 7 0.24
4 27 8 0.29
5 27 7 0.26
6 24 7 0.29
a Mice were immunized twice with 2 1 106 PFU of d301 or an equivalent amount of uninfected cell lysate and then underwent corneal challenge.
One month later, trigeminal ganglia were collected and tissue sections were hybridized to a probe for LATs.
RESULTS on the immune response of the host to the d301 mutant
virus.
Mechanism of protection against latent infection by
challenge virus
Duration of the protective immunity induced by a
We had shown previously that immunization of mice replication-defective virus
with replication-defective mutant viruses reduces the in-
cidence of latent infection of the trigeminal ganglia by the Because replication-defective viruses possess proper-
ties of both inactivated or subunit vaccines and live viruswt challenge virus as assayed by reactivation following
explant cocultivation (Morrison and Knipe, 1994). This vaccines, it was unclear how durable the immune re-
sponses to a replication-defective mutant virus would be.reduction could be due to decreased establishment of
latent infection or to decreased frequency of reactivation. Of particular interest to infection with HSV is protection
against latent infection because reduction in latency isTo distinguish between these two possibilities, we mea-
sured the numbers of trigeminal ganglion neurons ex- crucial to lessening the severity of recurrent disease and
the possibility for transmission. We could not measurepressing the LAT, a marker of latent infection (Stevens
et al., 1987; Croen et al., 1987), in animals immunized the duration of responses to inactivated virus because
UV-inactivated virus had not protected against latent in-twice with the replication-defective mutant virus d301 or
inoculated with control cell lysate and challenged with fection by challenge virus or elicited detectable neutraliz-
ing antibody titers in our previous studies (Morrison andvirulent virus by corneal inoculation. At 28 days postchal-
lenge, the trigeminal ganglia were removed from the ani- Knipe, 1994). As a consequence, we compared the dura-
bility of the immune response induced by d301 and itsmals and tissue sections from the ganglia were pro-
cessed for in situ hybridization using a probe specific replication-competent parental wt virus, KOS1.1 in pro-
tecting against disease and acute and latent infection,for LAT (Leib et al., 1989). The control animals showed
approximately 20 LAT-positive neurons per section (Ta- as outlined in Fig. 1. Groups of BALB/c mice (which are
susceptible to HSV-mediated keratitis and latent infec-ble 1) while the d301-immunized animals showed a LAT-
positive neuron in only about one in four sections (Table tion (Harbour et al., 1981; Foster et al., 1986)) were immu-
nized s.c. in the rear flank with 2 1 106 PFU of d301,1). These results allowed two conclusions about the
mechanism of protection against latent infection. First, KOS1.1, or an equivalent amount of control cell lysate,
and were immunized again 1 month later. Sera wereimmunization with d301 reduced the number of LAT-posi-
tive neurons (P  0.01) and therefore likely reduced the collected after each immunization to assess primary and
secondary HSV-specific, neutralizing antibody responses.number of neurons that are latently infected by challenge
virus. Thus, the protective effect was not simply a reduc- At 1, 4, and 7 months after the second immunization,
sera were again collected, and a cohort of mice wastion in the ability of the latently infected neurons to reacti-
vate, the parameter measured previously (Morrison and sacrificed to assess the HSV-specific, T cell proliferative
response. Subsets of the mice were then challenged byKnipe, 1994). Second, as evidenced by the lack of LAT-
positive neurons, d301 did not spread from the site of inoculation of virulent HSV-1 onto scarified corneas in
an amount equivalent to 5 to 15 times the dose requiredimmunization and establish latent infection in the trigemi-
nal ganglion neurons, thereby saturating the reservoir of to produce encephalitis in 50% of the mice. The eyes of
the mice were swabbed daily through 4 days postchal-sites for latent infection in the trigeminal ganglion. In-
stead, the mechanism of protection seemed to be based lenge to determine viral titer in the tear film as a measure
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FIG. 1. Schematic representation of the experiment designed to test duration of immune responses and protection. The upper horizontal time
line shows the full time course of the experiment. The lower horizontal line shows expanded view of procedures surrounding each challenge at 1,
4, or 7 months after the final immunization. Imm., s.c. immunization; Ab, serum collection for determination of neutralizing antibody titers; T,
assessment of splenic T cell proliferative responses in cohort animals; challenge, corneal inoculation of challenge virus; eye swabs, daily sampling
of tear film for determination of viral titer; keratitis scores, periodic examination of eyes for signs of disease (also indicates time period of evaluation
for signs of encephalitis); react, explant and coculture of dissociated trigeminal ganglia for determination of latent infection.
of acute replication. The mice were also monitored at but then remained constant through the following 7-
month period (Fig. 2A). Complement-independent neu-regular intervals for signs of encephalitis and keratitis.
Surviving mice were sacrificed 28 days after challenge to tralizing antibody titers of these same sera were lower
but were also similar for wt and mutant-infected miceassess the presence of latent infection in the trigeminal
ganglia. and remained roughly constant for 1–7 months after im-
munization (Fig. 2B).Duration of immune responses. Sera collected from
five or six mice of each immunization group were tested To examine the durability of a T cell memory response,
we examined T cell proliferative responses at variousfor HSV-specific neutralizing antibody in a CPE inhibition
assay. Titration of complement-dependent neutralizing times after immunization. We detected a strong T cell
proliferative response from splenocytes of either mutantantibodies (Fig. 2A) showed a primary antibody response
21 days after the first immunization with mutant or wt or wt virus-immunized mice at 1, 4, and 7 months after
immunization (Fig. 3). The response was HSV-specific invirus. The titers were augmented greatly and to similar
extents by secondary immunization with the mutant or that control supernatant placed in culture stimulated only
low levels of incorporation compared to responses towt virus. The titers in both mutant and wt virus-immunized
mice declined by 60–75% during the ensuing 3 weeks HSV-infected lysate (Figs. 3A and 3B), except that back-
FIG. 2. Neutralizing antibody titers in sera from immunized mice. Sera were collected from groups of six mice at the indicated times after
immunization, and HSV-specific neutralizing antibody titers of pooled sera were determined in a CPE inhibition assay. Titers shown represent a
statistical approximation of the reciprocal of the highest serum dilution giving 50% inhibition of CPE. CL, control cell lysate. (A) Complement-
dependent titers; (B) complement-independent titers.
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immunized with wt virus through at least 7 months after
immunization, and that HSV-specific immunity existed in
the mutant virus-immunized mice at each time of chal-
lenge.
Duration of protection against acute viral replication in
the eye. We assessed whether the immune response
elicited by immunization with replication-defective virus
maintained over time the capacity to reduce viral replica-
tion at the initial site of infection in the eye. Less virus
was shed in the tear film of mice immunized with mutant
virus than in mice inoculated with control cell lysate
when both groups of mice were challenged 1 month later
(Fig. 4A). This capacity of the immune response to reduce
viral titer in the eye was maintained in mice challenged
at 4 or 7 months after the final immunization (Figs. 4B
and 4C). Differences in viral eye titer of 1 to 2 log between
control and immunized mice were apparent as early as
1 day after infection. Mice immunized with mutant or wt
virus showed similar reductions in eye titer at 1 and 4
months, and the reduction was strikingly equivalent at 7
months (Fig. 4).
Duration of protection against encephalitis and kerati-
tis. By 5 days postchallenge, mice inoculated twice with
control cell lysate uniformly developed signs of encepha-
litis when challenged at 1, 4, or 7 months after immuniza-
tion: 88, 100, and 86% of the mice eventually succumbed
to infection at the three times, respectively. In contrast,
mice immunized twice with replication-defective or wt
virus showed no signs of encephalitis whether chal-
lenged at 1, 4, or 7 months after immunization. Severe
keratitis with stromal lesions also was observed in mice
inoculated with control cell lysate, with mean keratitis
scores reaching 3/ after challenge at all three times
(Fig. 5). Immunization with mutant or wt virus completely
protected mice challenged at 1 or 4 months from devel-
opment of stromal disease (Figs. 5A and 5B) and pro-
tected most mice challenged at 7 months (Fig. 5C). How-
ever, at 7 months, focal lesions of the cornea were seen
in three of the eyes of both mutant and wt virus-immu-
nized mice beginning 14 days after challenge. In 2/14 or
1/12 eyes from mutant or wt-immunized mice, respec-
FIG. 3. T cell proliferative response in immunized mice. Splenocytes tively, these lesions increased in severity to 3–4/. Histo-
from two mice per group were collected and pooled and depleted of B logic examination of the lesions revealed heavy infiltra-
cells at (A) 1, (B) 4, and (C) 7 months after immunization. The remaining tion by mononuclear cells compared to unaffected eyes
mononuclear cells were placed in culture in quadruplicate with partially
(data not shown). Whether damage to the corneas waspurified, UV-inactivated HSV or control supernatant. Values represent
mediated by viropathologic or immunopathologic mecha-the mean cpm { SD of [3H]thymidine on Day 4 of culture.
nisms could not be determined. Thus, there was less
acute replication of challenge virus in the eyes of mutant
virus-immunized mice and lower incidence of diseaseground proliferation was much higher at 7 month (Fig.
3C). Furthermore, the proliferative response of spleno- compared with control mice at all times although there
was some evidence of waning protection by 7 monthscytes from mutant virus-immunized mice was maintained
at a level nearly equivalent (1 month) or equivalent (4 in both wt and mutant virus-immunized mice.
Duration of protection against latent infection. We as-and 7 months) to that seen in mice immunized with wt
virus. These results indicated that mice immunized with sessed whether the immune response to replication-de-
fective virus maintained over time its capacity to de-replication-defective virus maintained neutralizing anti-
body and T cell proliferative responses as well as mice crease latent infection of the nervous system by chal-
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tent infection with the capacity for reactivation (Leib et
al., 1991; Jacobson et al., 1993). When challenged at 1
month after immunization, none of the ganglia from wt
virus-immunized mice and only 17% of ganglia from mu-
tant virus-immunized mice contained reactivating chal-
lenge virus. Cultures of all ganglia from surviving mice
inoculated with control cell lysate showed evidence of
FIG. 4. Reduction of challenge virus replication in the eye. Mice were
challenged at: (A) 1, (B) 4, or (C) 7 months after final immunization.
Samples of tear film were collected daily, and titer of infectious virus
as a measure of acute replication was assessed by standard plaque
assay. All samples contained infectious virus, and the values shown
represent the mean titer of samples from five or six mice per group
{ SEM.
lenge virus. Twenty-eight days after challenge, the
FIG. 5. Prevention of HSV-mediated keratitis in mutant virus-immu-trigeminal ganglia of surviving mice were assayed for the
nized mice. The eyes of groups of mice challenged at: (A) 1, (B) 4, orpresence of latent, reactivatible virus by tissue explant,
(C) 7 months after the final immunization were evaluated for signs of
dissociation, and coculture with permissive cell mono- keratitis at the indicated times postchallenge. Values represent the
layers. The dissociation assay was used because it is mean score of all eyes in each immunization group. The asterisk indi-
cates death of the majority of mice.regarded as the most sensitive means of assessing la-
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TABLE 2 determine viral titer. Titers of wt virus rose on Days 1–
3 postinoculation, but titers of mutant virus declined pro-Reduction of Latent Virus in Trigeminal Ganglia
gressively in footpads of inoculated mice (Fig. 6). In addi-
Fraction of ganglia with reactivating virusa from mice tion, mutant virus is undetectable within 1 day after inocu-
challenged at the indicated time after immunization: lation onto the cornea while wt virus titers increase by
Immunization 4 logs (Babu et al., 1996). These observations support
group 1 month 4 months 7 months
the contention that the mutant virus, d301, is replication-
defective in vivo as well as in tissue culture (Gao andExpt 1
Cell lysate 2/2 n.d.c 2/2 Knipe, 1989), and that its parent, the KOS1.1 strain, does
d301 1/6 (P  0.107)b 0/10 5/12 (P  0.231) replicate in vivo even though it is attenuated for virulence.
KOS1.1 wt 0/6 (P  0.036) 1/10 2/12 (P  0.066) A second important observation from these experi-
Expt 2
ments was that in contrast to the cornea, where infec-Cell lysate 10/12 10/10
tious replication-defective virus is rapidly cleared (Babud301 1/8 (P  0.003) 2/8 (P  0.002)
KOS1.1 wt 1/8 (P  0.003) 2/8 (P  0.002) et al., 1996), the mutant virus was recovered in an infec-
tious form in the footpad tissue for the 3-day interval of
a Assayed by cocultivation of dissociated ganglia. one experiment (Fig. 6A) and up to 6 days after inocula-b Compared to control cell lysate-inoculated mice by Fisher’s exact
tion in a second experiment of longer duration (Fig. 6B).test.
Titration on Vero cells of Day 1 and Day 3 samples fromc Not determined.
d301 mutant-infected mice showed no plaques (results
not shown), confirming that the virus persisting in the
footpads was truly input mutant virus. The persistencereactivating virus (Table 2, Expt 1), consistent with previ-
ous observations (Morrison and Knipe, 1994). Mice chal- of the mutant virus in an infectious form may prolong the
period of time during which infection and expression oflenged at 4 months after immunization also were appar-
ently protected from latent infection of the trigeminal gan- viral gene products occurs, thereby increasing the host
immune response to the replication-defective virus evenglion by challenge virus: 0 and 10% of ganglia from
mutant and wt virus-immunized mice, respectively, con- if the virus does not spread from the primary cells it
infects.tained reactivating virus. These data from the 4-months
time point could not be compared with time-matched
controls, however, because all mice inoculated with con- DISCUSSION
trol cell lysate died as a result of challenge virus infec-
This work has addressed the mechanisms by whichtion. A separate experiment in which more control mice
a live virus induces protection against a persistent infec-survived the challenge confirmed the apparent protection
tion and, specifically, how a replication-defective mutantseen at 1 and 4 months (Table 2, Expt 2). At 7 months,
of HSV induces protection against latent infection byall control ganglia but only 17% of ganglia from mice
challenge HSV. We have shown that immunization withimmunized with wt virus contained reactivating challenge
the mutant virus reduces the number of trigeminal gan-virus. Although the mice immunized with wt virus showed
glion neurons expressing the LAT transcript, arguing thata reduction in latent infection, the reduction was not sta-
the number of neurons latently infected by challenge vi-tistically significant. Reduction in the incidence of reacti-
rus was reduced by a mechanism other than establish-vation was observed also in mutant virus-immunized
ment of latency in those neurons by the immunizing virus.mice in which 42% of trigeminal ganglia showed reactiva-
Second, the duration of immunity induced by the mutanttion, but this difference was also not statistically signifi-
virus at the chosen dose appeared to be nearly equiva-cant. These reactivation data indicate that protection
lent to the replication-competent parental virus, demon-against latent infection was maintained for at least 4
strating that the immunity induced by a replication-defec-months following immunization with either mutant or wt
tive mutant virus is durable like live viruses even though,virus.
like killed virus vaccines, the mutant virus cannot spread.In vivo replication phenotype of mutant virus. The ob-
Third, the mutant virus showed no evidence of replicationservation that a replication-defective virus effectively
in vivo but was present in an infectious form for severalstimulated long-term immunity analogous to live, replica-
days in the mouse footpad, raising the possibility thattion-competent virus by all parameters tested was some-
primary infection continues over an extended period ofwhat surprising. We investigated the possibility that the
time.replication-defective virus was as effective as wt virus in
stimulating long-term immunity because its genetic de- Mechanism of protection against latent infection
fect was somehow complemented in vivo, rendering it
replication-competent. Mice were inoculated with mutant Our experiments show that animals immunized with
the replication-defective mutant virus and challengedor wt virus in the footpad (as a form of s.c. immunization),
and footpad tissue was collected at various times to with virulent HSV-1 bear approximately 80-fold fewer
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FIG. 6. In vivo replication of KOS1.1 but not d301 in footpad tissue. Groups of mice were injected with 1 1 106 PFU per footpad of KOS1.1 or
d301, and footpad tissue was dissected from subsets of the mice at the indicated times. Infectious virus in the tissue homogenate was titrated by
standard plaque assay on S-2 cells. Values represent mean titer of four tissue samples per group { SEM. A and B show two separate experiments
carried out for different periods of time.
LAT-positive neurons than animals immunized with unin- animals immunized with the mutant virus and then chal-
lenged express LAT at 28 days after challenge. Further-fected cell extract and then challenged. We conclude
that immunization with the mutant virus reduces the num- more, LAT-positive neurons were not observed in dorsal
root ganglia following inoculation of d301 into the footpadber of latently infected cells and not merely the ability of
the latent virus to reactivate. It is conceivable that in (Morrison and Knipe, unpublished results). Therefore, the
protection induced by the mutant virus is not the conse-the immunized animals the challenge virus can establish
latency but not express LAT. In situ hybridization tech- quence of saturation of the latent infection sites by a less
virulent virus but rather appears to involve host immuneniques have not been able to detect HSV DNA during
latent infection, but a few recent studies have detected mechanisms. Other studies have, in fact, demonstrated
that specific subsets of T cells are required for protectionHSV DNA during latent infection through the use of in situ
PCR techniques (Ramakrishnan et al., 1994; Gressens et against latent infection by the challenge virus (L. A. Mor-
rison and D. M. Knipe, manuscript in preparation).al., 1994; Gressens and Martin, 1994; Mehta et al., 1995).
These papers differ in their conclusions regarding the
latently infected cells in that one reports that the number Duration of immunity induced by a replication-
of HSV DNA-positive neurons is 50- to 100-fold higher defective mutant virus
than the number of neurons expressing LAT (Ramakrish-
nan et al., 1994) while another concludes that the distri- The capacity to provide long-lasting, ideally life-long,
protection is an important attribute of an effective vac-bution of LAT-positive cells approximates the distribution
of HSV DNA-positive cells (Mehta et al., 1995). We are cine-induced immune response. Historically, live viral
vaccines have induced a more long-lived immunity thancurrently attempting to establish a reliable in situ PCR
method to address the question of whether immunization killed virus vaccines. A major concern about replication-
defective viruses has been that they might not induce areduces the number of neurons containing HSV DNA. If
the number of latently infected cells is truly reduced by durable immunity because they could not spread to criti-
cal sites during infection of the host, much like killedimmunization, the question remains as to whether the
viral genome is prevented from reaching the neuronal virus vaccines. Nevertheless, at the dose used in mice
in this study, the duration of immunity induced by thecell body or whether it reaches the neuronal cell body
but cannot establish a latent infection. mutant virus seemed comparable to the replication-com-
petent parental virus. The mice in this study were immu-It has been proposed that live, attenuated viruses can
protect against the establishment of persistent infection nized as young adults at 6 and 10 weeks of age, and
immunity was demonstrated to last until the mice areby a more virulent virus by occupying the cellular sites
of latency and interfering with subsequent infection (Rud nearly 11 months old. For virgin, female BALB/c mice this
protection covers approximately 2/3 of their adult lifespanet al., 1994). Although it seemed unlikely that a replica-
tion-defective mutant could populate trigeminal ganglion (Russell, 1966). The durability of immunity induced in
mice by the replication-defective HSV mutant appearsneurons after inoculation in the rear flank, our experi-
ments rule out a form of latency involving LAT expression to approximate that of vaccinia vectors expressing HSV
glycoprotein D (Rooney et al., 1988; Wachsman et al.,by the mutant virus in the trigeminal ganglion by demon-
strating that very few trigeminal ganglion neurons in the 1992) and may exceed that induced by glycoprotein sub-
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units (Meignier et al., 1987) where immunity against intra- of the mutant virus to elicit strong, durable immunity in
the absence of spread within the host. Further dose stud-cerebral challenge waned with increasing time after im-
munization. ies are needed to better compare the immune responses
induced by these two types of virus, but our results areIt is interesting to note that in mice challenged 7
months after immunization, disease prevention and ef- consistent with studies demonstrating that other replica-
tion-defective mutant viruses, including canarypox vec-fects on acute replication remained largely unchanged
from earlier times, but reduction of latent infection was tors (Cox et al., 1993) and vaccinia virus vectors (Sutter et
al., 1994), elicit immunity similar to replication-competentless dramatic. These results suggest two things. First,
protection against latent infection may be the most sensi- viruses. The survival of mutant virus in an infectious form
in vivo and continued primary infection may provide ative indicator of the efficacy of long-term protection
against HSV infection. Consequently, even by the most way to reconcile current observations on the vaccine
capabilities of replication-impaired mutant viruses withsensitive criterion, immunization with d301 was effective
long-term in reducing challenge virus infection. Second, dogma about viral vaccines which holds that live forms
of viral vaccines effectively stimulate immunity as a con-while immune functions operating to reduce primary rep-
lication in the eye are still intact, those necessary to sequence of virus replication and spread (White and Fen-
ner, 1986; Mims et al., 1993).prevent virus spread to the nervous system and/or estab-
lishment of latent infection may not be operating as effec-
tively at late times after immunization. Conceivably, one ACKNOWLEDGMENTS
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